Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.59 |
| ▸ | CNR1 | P21554 | 13/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375910 | 0.84 | MAPT (0.44) | CNR2CNR1 | |
| SCHEMBL1376099 | 0.83 | MET (0.43) | CNR2CNR1KDM4EMEN1KMT2A | |
| SCHEMBL1372393 | 0.83 | CNR2 (0.44) | CNR2CNR1 | |
| SCHEMBL1372625 | 0.81 | AHR (0.50) | CNR2CNR1 | |
| SCHEMBL1372681 | 0.80 | CNR1 (0.66) | CNR2CNR1KDM4EMEN1CYP1A2 | |
| SCHEMBL1373635 | 0.79 | CNR1 (0.65) | CNR2CNR1KDM4EMEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL1373638 | 0.79 | CNR1 (0.65) | CNR2CNR1KDM4EMEN1CYP1A2 | |
| SCHEMBL454334 | 0.78 | ALDH1A1 (0.40) | KDM4EMEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1372995 | 0.77 | CNR1 (0.57) | CNR2CNR1KDM4EMEN1CYP1A2 | |
| SCHEMBL3051026 | 0.76 | L3MBTL1 (0.50) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394995-B1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-8334236-B2 | Ring-fused 2-pyridone derivatives and herbicides | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-12-18 | — | — | US | disclosed |
| EP-2394995-A1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | Kumiai Chemical Industry CO., LTD. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110287937-A1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287937-A1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | CBR3, CBR1, CHRM1 | CNR2 516/4885CNR1 327/4885KDM4E 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.